Combination Products - PowerPoint PPT Presentation

1 / 9
About This Presentation
Title:

Combination Products

Description:

75 years of excellence. Combination Products ... 75 years of excellence. Question 3. Use review process appropriate to the component ... – PowerPoint PPT presentation

Number of Views:33
Avg rating:3.0/5.0
Slides: 10
Provided by: prop245
Learn more at: https://www.fda.gov
Category:

less

Transcript and Presenter's Notes

Title: Combination Products


1
Combination Products
  • NEMAs Comments for the Office of Combination
    Products Public Hearing

Terry Sweeney, Philips Medical Systems
2
Question 2
  • Safety and Effectiveness should be considered on
    a component basis
  • Imaging Contrast Agent
  • Imaging Device (Magnetic Resonance, Ultrasound,
    etc.)
  • Effectiveness should be delegated to the
    component with the Primary Function
  • Imaging system creates the image, Imaging system
    has the primary function.

3
Question 2 - cont.
  • Center with appropriate expertise in the primary
    function should lead the review of effectiveness
  • CDRH should be lead reviewer for effectiveness of
    imaging systems using contrast agents that have
    been approved for safety by CDER.

4
Question 3
  • Use review process appropriate to the component
  • Contrast Agent Drug safety CDER
  • New drug
  • Revised dosing
  • Imaging Device Imaging Efficacy CDRH
  • New indication
  • Expanded indication

5
Question 4
  • Use Application appropriate for the component
  • Contrast Agent Drug Application processes
  • NDA, aNDA
  • Imaging Device Device application processes
  • 510(k), PMA

6
Question 5
  • Use Quality System appropriate for the component
  • Contrast Agent cGMP
  • Imaging Device QSR

7
Question 6
  • Use adverse event reporting system appropriate
    for the cited component
  • Contrast Agent Adverse Experience Reports
  • Imaging Device Medical Device Reports (MDR)

8
Question 7
  • Separate cross labeling requirements
  • Use Least Burdensome provisions to set
    appropriate regulatory controls
  • Intended Use statements may be distinct based
    upon safety risk
  • Contra-indications may be applied to only one OR
    both components
  • Cross-reference high-risk issues
  • De-couple component-specific issues (i.e.
    effectiveness)

9
Question 7 - cont.
  • Allow manufacturers of each component of a
    combination product to modify labeling in line
    with a high degree of patient protection
  • Pharmacology Agent manufacturer
  • Imaging effectiveness Device manufacturer
  • Allow Center with expertise in each component to
    review labeling for that component
  • Contrast Agent CDER
  • Imaging Device CDRH
Write a Comment
User Comments (0)
About PowerShow.com